ProAxsis Limited, the Belfast-based diagnostics company, today announces an expansion of its activities in Asia, via a partnership with Kyberlife, a Singapore-based company offering a novel e-commerce platform.

The partnership will initially enable the company’s existing product portfolio, including laboratory-based assays for the active forms of Neutrophil Elastase and Proteinase 3, and a point-of-care test for Neutrophil Elastase (NEATstik®) to be listed on the site.  The company will also have the option to add in new products as they become commercially available in Europe.

Dr David Ribeiro, Chief Executive Officer at ProAxsis, said: “Kyberlife offers the first open marketplace in Asia with an easy-to-use platform that hosts a multitude of global healthcare vendors, including companies such as Roche and Merck.  We’re delighted to be able to make it easier for laboratories across Asia, a key market for our respiratory diagnostics, to be able to make purchases from our portfolio of products.”

Further information on ProAxsis’ range of products can be found at

About ProAxsis

ProAxsis Limited is a global diagnostics company, based in Northern Ireland, with a specific focus on active protease biomarkers. The company currently commercialises activity-based immunoassays targeting Neutrophil Elastase (NE) and Proteinase 3, as biomarkers of lung infection and inflammation in chronic respiratory diseases such as COPD, cystic fibrosis and bronchiectasis. 

This technology has been translated into a point-of-care test (NEATstik®), to enable ongoing monitoring of active NE levels.  Recently published data has shown that measuring active NE levels using NEATstik® enables identification of patients with airway bacterial infection and those patients at highest risk of suffering pulmonary exacerbations over the subsequent 12 months. 

The company has significantly expanded its product portfolio, via the recent in-licensing of a novel bone health assay from the University of Geneva, and a COVID-19 serology assay from AstraZeneca.

In addition to proteases, the company also has significant expertise in the measurement of other inflammatory biomarkers, including IL-6, IL-8 and TNF-alpha.  Grant-funded R&D funded projects for a variety of targets remain a key area of focus.

Aside from the provision of assays, ProAxsis can offer sample analysis at its purpose-built laboratory facility in Belfast and is currently supporting a number of pharmaceutical company-sponsored Phase I, II and III clinical trials.

ProAxsis is a fully owned subsidiary of Netscientific plc, the international life sciences and sustainability technology investment and commercialisation Group.

Share This :